Inmune Bio (INMB) Other Non-Current Liabilities (2021 - 2023)
Inmune Bio (INMB) posted Other Non-Current Liabilities of $804,000 for Q3 2023.
Powered by 
Analysis
Inmune Bio (INMB) Other Non-Current Liabilities (2021 - 2023) Analysis & Trends
At the end of FY2022, Inmune Bio's Other Non-Current Liabilities came in at $550,000.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Inmune Bio | 42.88 Mn | -49.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 804,000.00 |
| Dec 31, 2022 | 550,000.00 |
| Sep 30, 2021 | 244,000.00 |
| Jun 30, 2021 | 160,000.00 |
API Access
Inmune Bio Other Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-non-current-liabilities", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();